Education
About Us
Working with TipRanks
Follow Us
DBV Technologies SA - American (DBVT)
NASDAQ:DBVT
DBVT Analyst Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
DBVT Stock 12 Month Forecast
Average Price Target
$20.00
▲(52.79% Upside)
| Highest Price Target$21.00 | Average Price Target$20.00 | Lowest Price Target$19.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
LifeSci Capital
$19
Buy
45.15%
Upside
Reiterated
11/20/25
Optimistic Buy Rating for DBV Technologies Amid Promising VIASKIN Peanut Trial DevelopmentsLast week, DBV announced that the final paent visit was completed in the pivotal Phase 3 VITESSE trial tesng VIASKIN Peanut for 4–7- year-olds with peanut allergies, and topline data are ancipated before year-end. The study has a 12-month main treatment period and a primary endpoint assessing the proporon of treatment responders (i.e. peanut desensizaon) in the acve versus placebo arms. If successful, the study should support accelerated approval in this age group, with a BLA submission currently planned for H1 2026. We recently hosted a management dinner with DBV, where we discussed key trial design elements and expectaons for the readout (LINK to note). Here, the bar for success is achieving stascal significance, which requires the lower bound of the 2-sided 95% confidence interval to be ≥15%; of note, this threshold was narrowly missed in DBV’s previous PEPITES trial in 4–11-year-olds.
H.C. Wainwright
$16→$20
Buy
52.79%
Upside
Reiterated
10/30/25
Citizens JMP
$21
Buy
60.43%
Upside
Reiterated
09/16/25
Goldman Sachs
$7.25
Sell
-44.61%
Downside
Initiated
05/29/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
LifeSci Capital
$19
Buy
45.15%
Upside
Reiterated
11/20/25
Optimistic Buy Rating for DBV Technologies Amid Promising VIASKIN Peanut Trial DevelopmentsLast week, DBV announced that the final paent visit was completed in the pivotal Phase 3 VITESSE trial tesng VIASKIN Peanut for 4–7- year-olds with peanut allergies, and topline data are ancipated before year-end. The study has a 12-month main treatment period and a primary endpoint assessing the proporon of treatment responders (i.e. peanut desensizaon) in the acve versus placebo arms. If successful, the study should support accelerated approval in this age group, with a BLA submission currently planned for H1 2026. We recently hosted a management dinner with DBV, where we discussed key trial design elements and expectaons for the readout (LINK to note). Here, the bar for success is achieving stascal significance, which requires the lower bound of the 2-sided 95% confidence interval to be ≥15%; of note, this threshold was narrowly missed in DBV’s previous PEPITES trial in 4–11-year-olds.
H.C. Wainwright
$16→$20
Buy
52.79%
Upside
Reiterated
10/30/25
Citizens JMP
$21
Buy
60.43%
Upside
Reiterated
09/16/25
Goldman Sachs
$7.25
Sell
-44.61%
Downside
Initiated
05/29/25
Best Analysts Covering DBV Technologies SA - American
1 Month
xxx
Success Rate
15/26 ratings generated profit
Average Return
+6.77%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 57.69% of your transactions generating a profit, with an average return of +6.77% per trade.
3 Months
xxx
Success Rate
13/26 ratings generated profit
Average Return
+9.72%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +9.72% per trade.
1 Year
Success Rate
14/26 ratings generated profit
Average Return
+30.87%
reiterated a buy rating 3 months ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +30.87% per trade.
2 Years
xxx
Success Rate
15/26 ratings generated profit
Average Return
+45.44%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 57.69% of your transactions generating a profit, with an average return of +45.44% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
DBVT Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
8
5
5
2
2
Buy
0
0
0
2
3
Hold
8
10
9
9
8
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
15
14
13
13
Each month's total comprises the sum of three months' worth of ratings.
DBVT Financial Forecast
DBVT Stock Forecast FAQ
What is DBVT’s average 12-month price target, according to analysts?
Based on analyst ratings, DBV Technologies SA - American’s 12-month average price target is 20.00.
What is DBVT’s upside potential, based on the analysts’ average price target?
DBV Technologies SA - American has 52.79% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is DBVT a Buy, Sell or Hold?
DBV Technologies SA - American has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
What is DBV Technologies SA - American’s price target?
The average price target for DBV Technologies SA - American is 20.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $21.00 ,the lowest forecast is $19.00. The average price target represents 52.79% Increase from the current price of $13.09.
The highest analyst price target is $21.00 ,the lowest forecast is $19.00. The average price target represents 52.79% Increase from the current price of $13.09.
What do analysts say about DBV Technologies SA - American?
DBV Technologies SA - American’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of DBVT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.